[1]
Toi, Y., Kimura, Y., Domeki, Y., Kawana, S., Aiba, T., Ono, H., Asou, M., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., Saito, R., Terayama, K., Kawashima, Y., Nakamura, A., Yamanda, S., Honda, Y. and Sugawara, S. 2019. Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study: BSA and nintedanib reduction/discontinuation. Sarcoidosis Vasculitis and Diffuse Lung Disease. 36, 1 (Mar. 2019), 74–78. DOI:https://doi.org/10.36141/svdld.v36i1.7383.